OR WAIT null SECS
- Advertise
- Contact Us
- Editorial Contacts
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2022 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Comprehensive Clinical Development Showcases Company Rebrand at the 2011 DIA Annual Meeting
Company News Release
Comprehensive Clinical Development
, formerly operating as Comprehensive NeuroScience, Inc., a clinical services company delivering high-quality clinical trials from Phase I-IV with three pharmacology units and five patient-focused Phase IIb-IV centers, has established its new brand identity, “Confidence in Comprehensive,” emphasizing the Company’s proficiency in conducting effective and efficient clinical trials.
Comprehensive
will unveil its new identity at the 2011 Drug Information Association (DIA) Annual Meeting , June 19-23, 2011, in Chicago, Illinois. Showcasing its total rebrand, Comprehensive will capitalize on its commitment to delivering efficient studies conducted with high quality and pristine data at booth #1539 during the annual meeting.
The new face of Comprehensive reflects the Company’s diverse therapeutic expertise and suite of clinical services. Articulating Comprehensive’s depth and breadth in therapeutic expertise with the rebrand, Comprehensive’s unwavering commitment to both its internal and external customers remains.
During the DIA Annual Meeting, Royce A. Morrison, M.D., M.S., Comprehensive Clinical Development’s chief medical officer, will present his findings on technology in early phase studies and strategies to optimize the methods utilized. His presentation, Track 4 (A), titled, “Nonclinical and Early Clinical Translational Development,” is scheduled for Wednesday, June 22, from 1:30 – 3:00 p.m.